Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222521 · ClinicalTrials.gov registry record · Phase 3
Insulin Glargine Vs Standard Insulin Therapy
A Phase 3 study of Cystic Fibrosis-related Diabetes, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00222521 is a Phase 3 study of Cystic Fibrosis-related Diabetes that has completed, run by University of Minnesota. The registered enrollment target is 20 participants, below the 106-participant average among 10 other Cystic Fibrosis-related Diabetes trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00222521, a Phase 3 study of Cystic Fibrosis-related Diabetes, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
Conditions Studied
Interventions
- DRUG Glargine insulin
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222521
The ClinicalTrials.gov registry entry for NCT00222521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 10 other Cystic Fibrosis-related Diabetes trials with a reported enrollment target (81% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis-related Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Glargine insulin is the first listed.
NCT00222521 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00222521 about?
NCT00222521 is a clinical study titled "Insulin Glargine Vs Standard Insulin Therapy". This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
What is the current status of trial NCT00222521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2003-04. Estimated completion is 2005-08.
What conditions does trial NCT00222521 study?
This clinical trial studies the following conditions: Cystic Fibrosis-related Diabetes.
What interventions are being tested in trial NCT00222521?
The interventions under investigation include: Glargine insulin (DRUG).
Who is sponsoring clinical trial NCT00222521?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00222521 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis-related Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bionic Pancreas in CFRD
RECRUITING · Phase 3
-
Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
RECRUITING · Phase 1
-
ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
FEED-Cystic Fibrosis (FEED-CF)
RECRUITING · NA
-
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.